CD40 and neoplasm: In contrast, agonistic CD40 mAb therapy did not enhance IDO1 expression in CD45+ leukocytes, and the relative level of expression was considerably lower in leukocytes than what was observed in tumor endothelial cells after agonistic CD40 mAb therapy (Supplemental Fig S4C).